Ortega Aramburu J J, Olivé Oliveras T, Javier Manchón G, Bastida Vila P, Sánchez C, Giralt López J
Sección de Hematología, Hospital Materno Infantil, Vall d'Hebrón, Spain.
Sangre (Barc). 1991 Feb;36(1):7-14.
Both intensification therapies with high-doses ARA-C and bone marrow transplant, allogeneic (BMT) or autologous (ABMT), have proved effective in relapse prevention in ANLL. The present study combines both treatments. METHODS. Remission induction treatment was DAE combination. The first intensification consisted of HD ARA-C and mitoxantrone and the second HD ARA-C and AMSA. CNS prophylaxis consisted of 6 doses of i.t. ARA-C and MTX. Later, patients in remission with HLA-compatible donor received BMT and those without it, ABMT with "ex vivo" treatment of the bone marrow with ASTA-Z. Pre-BMT treatment was the same in both cases: fractionated total body irradiation (TBI) and cyclophosphamide in patients over 3 years of age; in patients under 3 busulfan was given instead of TBI. PATIENTS. Between April 88 and March 90, 18 patients (age 3 months to 14 years) were included. FAB subtypes were M1 + M2: 4; M3: 2; M4: 4; M5: 5; M6: 1; M7: 2. Two patients died of cranial haemorrhage before the 10th day, 15 achieved complete remission (CR) after one or two induction treatments and 1 only attained CR after the first intensification.
1 patient with M7 relapsed after the 2nd intensification. Of the remaining 15, five received BMT and ten ABMT. Average interval between CR and transplant was 4 months (3 to 8). Of the 5 with BMT, one died from progressive obliterating bronchiolitis at 9 months and the other four continued in CR for 6 to 28 months. Of the 10 with ABMT none died from complications, 2 suffered early relapse and 8 continued in CR for 6 to 28 months.(ABSTRACT TRUNCATED AT 250 WORDS)
大剂量阿糖胞苷强化治疗以及骨髓移植,包括异基因(BMT)或自体(ABMT)骨髓移植,均已被证明在急性非淋巴细胞白血病(ANLL)的复发预防中有效。本研究将这两种治疗方法相结合。方法:缓解诱导治疗采用DAE方案。第一次强化治疗包括大剂量阿糖胞苷和米托蒽醌,第二次强化治疗包括大剂量阿糖胞苷和安吖啶。中枢神经系统预防包括6次鞘内注射阿糖胞苷和甲氨蝶呤。之后,有 HLA 相合供者的缓解期患者接受 BMT,没有相合供者的患者接受用阿斯塔 - Z对骨髓进行“体外”处理的 ABMT。两种情况下BMT前的治疗相同:3岁以上患者采用分次全身照射(TBI)和环磷酰胺;3岁以下患者用白消安代替TBI。患者:在1988年4月至1990年3月期间,纳入了18例患者(年龄3个月至14岁)。FAB亚型为M1 + M2:4例;M3:2例;M4:4例;M5:5例;M6:1例;M7:2例。2例患者在第10天前死于颅内出血,15例患者经一或两次诱导治疗后达到完全缓解(CR),1例仅在第一次强化治疗后达到CR。
1例M7患者在第二次强化治疗后复发。其余15例中,5例接受BMT,10例接受ABMT。CR与移植之间的平均间隔为4个月(3至8个月)。接受BMT的5例患者中,1例在9个月时死于进行性闭塞性细支气管炎,另外4例持续CR 6至28个月。接受ABMT的10例患者中,无1例死于并发症,2例早期复发,8例持续CR 6至28个月。(摘要截断于250字)